Loading...
Phase II, Multicenter, Randomized Trial of Docetaxel plus Prednisone with or Without Cediranib in Men with Chemotherapy‐Naive Metastatic Castrate‐Resistant Prostate Cancer
LESSONS LEARNED. The negative results are consistent with the negative results of large phase III trials in which docetaxel plus antiangiogenic agents were used in patients with metastatic castrate‐resistant prostate cancer (mCRPC). The negative data underscore that, despite a sound biological ratio...
Na minha lista:
| Udgivet i: | Oncologist |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley & Sons, Inc.
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6738301/ https://ncbi.nlm.nih.gov/pubmed/31152080 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0331 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|